Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH)
Objective and design
To characterize the impact of inflammatory process and oxidative stress in the degree of benign prostatic hyperplasia (BPH), a common condition in which chronic inflammation plays a crucial role, we investigated the effect of different plant extract preparations in an in vivo model of BPH as new therapeutic target.
BPH was made in rats with daily administration of testosterone propionate (3 mg/kg) for 14 days.
Rats were randomized into different groups to receive oral administration of plant extract preparations: Serenoa repens with selenium (SeR 28.5 mg/kg associated with Se 0.005 mg/kg), Teoside (2 mg/kg), and Puryprost (14 mg/kg containing Teoside 50% 2 mg/kg and Epilobium 12 mg/kg).
After 14 days, rats were killed and histological changes, prostate weight and apoptotic pathways were assayed.
The results obtained demonstrated that the association of treatments reduced prostate weight and hyperplasia, while treatment with Puryprost demonstrated a greater trend of protection compared to the other treatments.
Thus, our results indicate that plant extract could be considered as new useful therapy in the treatment of BPH with particular attention on Puryprost that represents a rational approach to reduce BPH through modulation of inflammatory process and anti-oxidant process.
KeywordsBenign prostatic hyperplasia Inflammation Oxidative stress Natural extract
The authors would like to thank Maria Antonietta Medici for her excellent technical assistance during this study and Mr. Francesco Soraci for his secretarial and administrative assistance and Miss. Valentina Malvagni for her editorial assistance with the manuscript.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Availability of data and material
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
- 7.Minutoli L, Altavilla D, Marini H, Rinaldi M, Irrera N, Pizzino G, et al. Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of Serenoa repens, selenium and lycopene. J Biomed Sci. 2014;21:19. https://doi.org/10.1186/1423-0127-21-19.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Altavilla D, Minutoli L, Polito F, Irrera N, Arena S, Magno C, et al. Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia. Br J Pharmacol. 2012;167(1):95–108. https://doi.org/10.1111/j.1476-5381.2012.01969.x.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Paterniti I, Impellizzeri D, Di Paola R, Esposito E, Gladman S, Yip P, et al. Docosahexaenoic acid attenuates the early inflammatory response following spinal cord injury in mice: in-vivo and in-vitro studies. J Neuroinflammation. 2014;11:6. https://doi.org/10.1186/1742-2094-11-6.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Cordaro M, Paterniti I, Siracusa R, Impellizzeri D, Esposito E, Cuzzocrea S. KU0063794, a dual mTORC1 and mTORC2 inhibitor, reduces neural tissue damage and locomotor impairment after spinal cord injury in mice. Mol Neurobiol. 2016. https://doi.org/10.1007/s12035-016-9827-0.CrossRefPubMedGoogle Scholar
- 15.Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics 2004 CA: a cancer journal for clinicians. 2004;54(1):8–29.Google Scholar
- 20.Lin-Tsai O, Clark PE, Miller NL, Fowke JH, Hameed O, Hayward SW, et al. Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. Prostate. 2014;74(6):669–79. https://doi.org/10.1002/pros.22785.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Larre S, Camparo P, Comperat E, Boulbes D, Haddoum M, Baulande S, et al. Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures. Asian J Androl. 2012;14(3):499–504. https://doi.org/10.1038/aja.2011.132.CrossRefPubMedGoogle Scholar
- 26.Cordaro M, Impellizzeri D, Siracusa R, Gugliandolo E, Fusco R, Inferrera A, et al. Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia. Toxicol Appl Pharmacol. 2017;329:231–40. https://doi.org/10.1016/j.taap.2017.06.005.CrossRefPubMedGoogle Scholar
- 27.Larre S, Tran N, Fan C, Hamadeh H, Champigneulles J, Azzouzi R, et al. PGE2 and LTB4 tissue levels in benign and cancerous prostates. Prostaglandins Other Lipid Mediat. 2008;87(1–4):14–9. https://doi.org/10.1016/j.prostaglandins.2008.05.001.CrossRefPubMedGoogle Scholar
- 28.Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P, Koutsilieris M. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res. 2005;25(4):3123–33.PubMedGoogle Scholar